a great discussion on FDA approach.Why not do one on Romosozumab which -in contrast-is both first in class and phenomenally effective.Tony Russell
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
